← All countries · Western Pacific
85%
MCV1
2025 · WHO/UNICEF estimate
82%
DTP3
2025 · WHO/UNICEF estimate
76%
IPV complete
2025 · WHO/UNICEF estimate
82%
HepB3
2025 · WHO/UNICEF estimate
36,590
Measles cases
2025 reported
1,396
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 85%2025 · WHO/UNICEF estimate | 84.5% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 85%2025 · WHO/UNICEF estimate | 85.3% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 82%2025 · WHO/UNICEF estimate | 82.0% | B · good | |
| IPV1First dose of inactivated polio vaccine | 81%2025 · WHO/UNICEF estimate | 80.7% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 76%2025 · WHO/UNICEF estimate | 76.2% | D · poor | |
| MCV1First dose of measles-containing vaccine | 85%2025 · WHO/UNICEF estimate | 85.2% | B · good | |
| MCV2Second dose of measles-containing vaccine | 78%2025 · WHO/UNICEF estimate | 78.3% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 85%2025 · WHO/UNICEF estimate | 85.2% | C · weak | |
| HepB3Third dose of hepatitis B vaccine | 82%2025 · WHO/UNICEF estimate | 82.0% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 72%2025 · WHO/UNICEF estimate | 72.0% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 82%2025 · WHO/UNICEF estimate | 82.0% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 79.2%2025 · Administrative (country-reported) | 79.2% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 69%2025 · WHO/UNICEF estimate | 69.4% | B · good | |
| RotaCRotavirus vaccine, complete series | 71%2025 · WHO/UNICEF estimate | 70.8% | C · weak | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 57.1%2025 · Administrative (country-reported) | 57.1% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 83%2024 · WHO/UNICEF estimate | 98.3% | C · weak | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 83%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 83%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 36,5902025 | 128.1per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 7482025 | 2.6per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 2112025 | 0.5per 10,000 live births | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 1,3962025 | 4.9per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 2542025 | 0.9per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 3,9192025 | 13.7per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 502025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 72024 | 0.1per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 102025 | 0per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (48 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B-M1 | General/routine | live birth infant until first month |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y7 | General/routine | DT will given to children Y7 equal specific target 1st grade in elementary school |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | Surviving Infants (dose 1,2,3) and Children under 2 years (dose 4) |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M3 | General/routine | Surviving Infants (dose 1,2,3) and Children under 2 years (dose 4) |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M4 | General/routine | Surviving Infants (dose 1,2,3) and Children under 2 years (dose 4) |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 4 | M18 | General/routine | Surviving Infants (dose 1,2,3) and Children under 2 years (dose 4) |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 1 | M2 | General/routine · SUBNATIONAL | Surviving infants in last 3 months of 2025 data in 9 provinces (6 provinces in Papua Region, West Nusa Tenggara, Bali, DI Yogyakarta). Nationwide introduction planned in October 2026 |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 2 | M3 | General/routine · SUBNATIONAL | Surviving infants in last 3 months of 2025 data in 9 provinces (6 provinces in Papua Region, West Nusa Tenggara, Bali, DI Yogyakarta). Nationwide introduction planned in October 2026 |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 3 | M4 | General/routine · SUBNATIONAL | Surviving infants in last 3 months of 2025 data in 9 provinces (6 provinces in Papua Region, West Nusa Tenggara, Bali, DI Yogyakarta). Nationwide introduction planned in October 2026 |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Health workers. 2nd dose 1 month after 1st dose; 3rd dose after 6 month after 2nd dose |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Health workers, 2nd dose 1 month after 1st dose; 3rd dose after 6 month after 2nd dose |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | Health workers, 2nd dose 1 month after 1st dose; 3rd dose after 6 month after 2nd dose |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Live birth infant - given <H24 |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11 | HPV for females only | only given for 5th grade elementary school or 11 years of female |
| IPVIPV (Inactivated polio vaccine) | 1 | M4 | General/routine | Surviving infants |
| IPVIPV (Inactivated polio vaccine) | 2 | M9 | General/routine | Surviving infants |
| JE_LIVEATDJE-Livatd (Japanese Encephalitis live-attenuated) vaccine | 1 | M10 | General/routine · SUBNATIONAL | Only 9 districts at Bali Province and 14 districts in West Kalimantan province |
| MRMR (Measles and rubella) vaccine | 1 | M9 | General/routine | Surviving Infant (first dose), children under 2 years old (second dose), and 1st grade of elementary school or children Y7 (third dose) |
| MRMR (Measles and rubella) vaccine | 2 | M18 | General/routine | Surviving Infant (first dose), children under 2 years old (second dose), and 1st grade of elementary school or children Y7 (third dose) |
| MRMR (Measles and rubella) vaccine | 3 | Y7 | General/routine | Surviving Infant (first dose), children under 2 years old (second dose), and 1st grade of elementary school or children Y7 (third dose) |
| OPVOPV (Oral polio vaccine) | 1 | M1 | General/routine | Surviving infants |
| OPVOPV (Oral polio vaccine) | 2 | M2 | General/routine | Surviving infants |
| OPVOPV (Oral polio vaccine) | 3 | M3 | General/routine | Surviving infants |
| OPVOPV (Oral polio vaccine) | 4 | M4 | General/routine | Surviving infants |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose) |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M3 | General/routine | Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose) |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose) |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | Surviving infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M3 | General/routine | Surviving infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 3 | M4 | General/routine | Surviving infants |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y15-Y39 | Adults | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y15-Y39 | General/routine | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +W4 | Adults | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +W4 | General/routine | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Adults | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | General/routine | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Adults | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | General/routine | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Adults | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | General/routine | Child-bearing women (15Y-Y39); 2nd dose 4 weeks after 1st dose; 3rd dose 6 months after 2nd dose; 4th dose 1 year after 3rd dose; 5th dose 1 year after 4th dose. Doses are provided according to immunization status, specifically for women who have not yet reached T5 status. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y7-Y8 | General/routine | Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 7 | Y9-Y10 | General/routine | Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school |
| VITAMINAVitamin A supplements | 1 | M6-M11 | General/routine | Under 5 years |
| VITAMINAVitamin A supplements | 2 | M12-M59 | General/routine | Under 5 years |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.